Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Return on Equity (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Return on Equity for 15 consecutive years, with 0.15% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 25.0% to 0.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.15% through Dec 2025, up 25.0% year-over-year, with the annual reading at 0.17% for FY2025, 26.0% up from the prior year.
  • Return on Equity hit 0.15% in Q4 2025 for Ani Pharmaceuticals, down from 0.16% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 9392.5% in Q4 2023 to a low of 26324.0% in Q1 2023.
  • Historically, Return on Equity has averaged 1100.67% across 5 years, with a median of 0.1% in 2024.
  • Biggest five-year swings in Return on Equity: tumbled -2636404bps in 2023 and later surged 2633155bps in 2024.
  • Year by year, Return on Equity stood at 0.45% in 2021, then skyrocketed by 47bps to 0.24% in 2022, then skyrocketed by 3916309bps to 9392.5% in 2023, then tumbled by -100bps to 0.1% in 2024, then skyrocketed by 255bps to 0.15% in 2025.
  • Business Quant data shows Return on Equity for ANIP at 0.15% in Q4 2025, 0.16% in Q3 2025, and 5103.0% in Q2 2025.